Qingyun Pharma and Organon Announce Innovative Strategic Collaboration on Remeron® (Mirtazapine)

On November 8, 2023, Shanghai Qingyun Pharmaceutical Co., Ltd. (hereinafter referred to as “Qingyun Pharmaceutical”) and Organon (Shanghai) Pharmaceutical Co., Ltd. (hereinafter referred to as “Organon”) officially signed an agreement for Remeron during the 6th China International Import Expo.^®(Mirtazapine) Innovative Strategic Cooperation Agreement.

Mr. Shi Ming, Head of Commercial Excellence and Vice President, China, Organon; Ms. Lin Yuwei, Head of Classic Brand Marketing and Vice President, China, Organon; Ms. Yang Chunhua, Head of Multichannel and Digital Marketing, China, Organon; Ms. Cheng Lijun, Head of Central Nervous System Marketing, China, Organon; Mr. Yan Guowei, Chief Executive Officer of Qingyun Pharmaceutical; Mr. Jiang Yao, Chief Commercial Officer of Qingyun Pharmaceutical; Mr. Shen Sijiong, Chief Sales Officer of Qingyun Pharmaceutical; and Ms. Sun Yan, Director of Customer Excellence at Qingyun Pharmaceutical, among other leaders, attended the signing ceremony.

 Group Photo of Attending Leaders

Mr. Yan Guowei, CEO of Qingyun Pharma, expressed gratitude to Organon for its long-standing trust and support. Since the establishment of their partnership in 2020, Qingyun Pharma has continued to innovate and grow under Organon’s guidance, evolving from virtual representation to precision digital marketing. Remeron^®The innovative strategic partnership for (Mirtazapine) marks a milestone in the field of digital medical marketing. It also demonstrates how a mature branded product can enhance physician satisfaction and improve pharmaceutical company efficiency, thereby practicing a patient-centric innovative marketing model in the context of deepening reforms in China’s healthcare market. Yan Guowei stated that Qingyun Pharma will fully leverage the advantages of its omnichannel marketing team, both online and offline, to actively achieve broad coverage, high efficiency, and personalized academic services for physicians. While ensuring compliant operations, the company aims to establish best practices for digital marketing in China!

Mr. Yan Guowei, CEO of Qingyun Pharmaceuticals

Mr. Shi Ming, Head of Organon’s Commercial Excellence Department and Vice President for China, extended warm congratulations on the establishment of the strategic partnership between the two parties and expressed his best wishes for their future collaborative development.

Meanwhile, it was pointed out that the prevalence of depression in China is increasing year by year, with only 0.5% of patients receiving adequate treatment, and the prevalence among women exceeds that among men. As a patient-centric healthcare company dedicated to women’s health, Organon is helping to improve the current state of depression diagnosis and treatment in China. This year, Organon actively responded to national policies, with Remeron^®(Mirtazapine) was successfully shortlisted and won the bid in the eighth round of centralized procurement, significantly improving patients’ access to medication. Organon is excited that its high-quality products can reach a broader patient population and bring hope to their lives.

Through this collaboration with Qingyun Pharma, Organon is committed to implementing an omnichannel marketing strategy for Remeron via innovative approaches, providing personalized academic engagement for healthcare professionals to help enhance diagnostic and therapeutic standards.

Mr. Shi Ming, Head of Commercial Excellence & Vice President, China Region, Organon

Following the signing ceremony, the two parties engaged in a roundtable discussion on hot topics such as innovative business models and long-term development strategies.

Roundtable Discussion Photo

United in Purpose, “Depression” Meets Hope: The Signing Ceremony Concluded Successfully Amidst Warm Applause. Both parties will join hands to co-create an innovative business model, committed to providing high-quality clinical solutions for patients with depression and contributing to the Healthy China Strategy!

Qingyun Pharma is China’s leading digital omnichannel marketing platform. It provides healthcare enterprises with comprehensive digital marketing solutions, including data intelligence, system development, and digital marketing execution services. Qingyun Pharma boasts diverse physician engagement teams and communication channels, encompassing offline field representatives, online virtual representatives, and private-domain physician networks. Leveraging its proprietary SCRM (Social Customer Relationship Management) system, the company accumulates vast amounts of physician behavior data. Physician engagement activities are driven by intelligent algorithmic models, enabling truly personalized medical services and professional communication with physicians, thereby achieving the goal of precision marketing for pharmaceuticals and medical devices.

Organon is a global leader in the healthcare industry, with over 60 innovative medicines and healthcare solutions, committed to becoming the world’s leading healthcare company in women’s health. Guided by its corporate vision of “creating healthier, better days for every woman,” Organon provides innovative medicines and solutions across its core pillars—women’s health, established brands, and biosimilars—to improve the health and lives of women and their families worldwide, enabling healthier everydays.